Similar to BRAFi, mitogen/extracellular signal regulated kinase (MEK) inhibition controls tumor progression, but has been shown to negatively impact T cell priming and proliferation in vitro and in lymph nodes (173). Here, MAP2K7 is linked to neoplasm.